Trojan Bio

Company Overview

Snapshot

Founded in October 2021 by Anat Burkovitz, Amir Aharoni, and Noam Diamant, Trojan Bio operates with 1–10 employees. The company has secured funding across two disclosed rounds from two investors. In December 2023, Trojan Bio received Seed funding from Peregrine Ventures.

Business overview

Trojan Bio is a preclinical immunotherapy company focused on developing novel therapeutic antibodies for various cancers. The company's core technology involves "Trojan antibodies" that integrate viral peptides to activate the immune system, labeling cancer cells as virally infected to harness powerful anti-viral immunity for cancer eradication. Trojan Bio operates within the Health Tech & Life Sciences sector, specifically targeting the Drugs Discovery & Development market within Pharmaceuticals.

Company Intelligence Q&A

When was Trojan Bio founded?

Trojan Bio was founded in October 2021.

Who are the founders of Trojan Bio?

Trojan Bio was co-founded by Anat Burkovitz, Amir Aharoni, and Noam Diamant.

What is Trojan Bio's primary focus?

Trojan Bio is developing a novel class of therapeutic antibodies for the treatment of various cancers, utilizing viral peptides to activate the immune system.

Which investors have participated in Trojan Bio's funding rounds?

Trojan Bio has received funding from investors including Peregrine Ventures.